Modality
Cell Therapy
MOA
TNFi
Target
KRASG12D
Pathway
RAS/MAPK
T2DCFACC
Development Pipeline
Preclinical
Aug 2024
→ Aug 2029
PreclinicalCurrent
NCT07312820
2,446 pts·ACC
2024-08→2029-08·Recruiting
NCT07591992
1,892 pts·ACC
2025-05→TBD·Terminated
4,338 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-113.4y awayInterim· ACC
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2029-08-11 · 3.4y away
ACC
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07312820 | Preclinical | ACC | Recruiting | 2446 | BodyWt |
| NCT07591992 | Preclinical | ACC | Terminated | 1892 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |